Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The study addresses the question if a therapy with bendamustine plus rituximab is comparable
(non inferior) with the well-tried combination of fludarabine plus rituximab with regard to
event free survival (EFS) in recurrent low malignant Non-Hodgkin and mantle cell lymphomas.